RxDoctor Payments Data

Adriana Lucia, PA

Physician Assistant · Tucson, AZNPI 1144231549

Payments from drug & device makers

$2,090in general payments, 2019–2025

Across 85 payments — averaging $24.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$412
  • Sumitomo Pharma America, Inc.$347
  • Dendreon Pharmaceuticals LLC$260
  • Axonics, Inc.$98
  • Coloplast$94
  • Teleflex LLC$90
  • plus $788 from 19 others

What the payments were for

  • Food & beverage$1,84088%
  • Education$25012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,090 in reported general payments places this provider in the 80th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$165,529
Medicare patients
582
Services billed
6,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron261$268,771
GemtesaVibegron159$144,742
Estradiol461$30,064
Methenamine Hippurate119$16,225
Tamsulosin Hcl695$9,027
Mirabegron ErMirabegron14$8,443
Trospium Chloride73$5,085
Finasteride337$4,488
Tolterodine Tartrate ErTolterodine Tartrate26$2,677
Darifenacin ErDarifenacin Hydrobromide12$2,337
Potassium Citrate ErPotassium Citrate19$2,099
Solifenacin Succinate24$1,437
Trimethoprim15$1,206
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst71$1,163
Alfuzosin Hcl ErAlfuzosin Hcl36$1,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$412$268,771261 claims
Sumitomo Pharma America, Inc.Gemtesa$347$144,742159 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →